Intravitreal bevacizumab for peripapillary choroidal neovascular membranes.

nesh, Kaliki, and Shields) and Pediatric Ophthalmology and Ocular Genetics Services (Drs Ganesh and Levin), Wills Eye Institute, Thomas Jefferson University, Philadelphia, Pennsylvania. Correspondence: Dr Shields, Ocular Oncology Service, Wills Eye Institute, 840 Walnut St, Ste 1440, Philadelphia, PA 19107 ([email protected]). Author Contributions: Dr Shields had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Financial Disclosure: None reported. Funding/Support: This work was supported by the Eye Tumor Research Foundation (Dr Shields) and the Foerderer Fund (Dr Levin). Role of the Sponsors: The sponsors had no role in the design and conduct of the study; collection, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.